Semax

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) structurally derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10), with a Pro-Gly-Pro C-terminal extension added to improve metabolic stability. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered in Russia in 1991 as a pharmaceutical for use in ischemic stroke, transient ischemic attack, and cognitive impairment. It belongs to the melanocortin-related nootropic peptide class and is often grouped with peptide-based nootropics like Selank. For educational purposes only — the information that follows is a summary of published research and does not constitute medical advice or a recommendation for human use.

The primary mechanism of action reported in research involves upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in limbic brain regions. Animal models also suggest Semax modulates serotonergic, dopaminergic, and cholinergic neurotransmission, and preliminary evidence points to inhibition of enkephalin-degrading enzymes, which may prolong endogenous opioid peptide activity. Additionally, research in rodent models has demonstrated anti-inflammatory effects through modulation of cytokine expression in brain tissue following ischemic injury. The intranasal delivery route appears to allow direct transport to the CNS via the olfactory pathway, which may explain the relatively rapid onset reported in both clinical and self-report contexts.

The evidence base for Semax is more substantial than for most research peptides, though it is heavily skewed toward Russian-language publications and institutional trials that are difficult to independently audit by Western standards. Human clinical trials — primarily conducted in Russia — have examined Semax in stroke rehabilitation, optic nerve disease, and cognitive decline, with some studies reporting sample sizes in the range of 50–200 patients and measurable improvements on neurological scoring scales. A notable area of investigation involves its use in ischemic stroke, where published Russian trials (notably work from Gusev et al. and associated research groups through the 2000s) reported improved functional outcomes with intranasal administration. Animal studies — predominantly in rodents — demonstrate neuroprotective effects in models of ischemia, and enhanced spatial learning and memory consolidation. Anecdotal user reports from nootropics communities (Longecity, Reddit r/nootropics) consistently describe improved focus, verbal fluency, and a mild anxiolytic effect, with some users noting mood enhancement. These self-reports should be weighted accordingly — they are uncontrolled and subject to significant placebo confounding.

Dosing ranges reported in published research contexts vary considerably by indication and delivery method. Intranasal dosing in clinical trials has typically ranged from 200–900 mcg per day, often administered as divided doses across a course of several weeks. Some Russian clinical protocols describe 0.1% nasal drop formulations delivering approximately 50–100 mcg per spray. Subcutaneous injection has also been studied, with ranges in the 200–500 mcg per day range in some animal and preliminary human protocols. IMPORTANT: These ranges are reported from research and clinical trial contexts only — they do not constitute a dosing recommendation. Semax is not approved for human use by the FDA, MHRA, or EMA, and no safe or effective dose has been established outside registered clinical contexts.

In terms of legal status, Semax is a registered pharmaceutical in Russia and Ukraine, available there by prescription. In the United States, it is unscheduled and not FDA-approved, existing in a research-chemical grey zone — legal to purchase for research purposes but not for human consumption. The same broadly applies in the UK and EU, where it lacks MHRA or EMA approval and falls into unregulated research-chemical territory. In Australia, it is not TGA-approved and would be considered an unapproved therapeutic good. Sourcing quality is a significant concern: reputable vendors should provide third-party HPLC and mass spectrometry certificates of analysis (COA) confirming identity and purity above 98%, along with endotoxin testing given the intranasal/injectable routes. Lyophilized powder requiring reconstitution is the most common research form; pre-dissolved intranasal formulations require cold-chain integrity and carry higher contamination risk if improperly handled.